Efficacy and safety of a lactiplantibacillus plantarum and bifidobacterium bifidum complex for dry eye disease: a randomized, double-blind, placebo-controlled trial
Year: 2026
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Abstract: Dry eye disease (DED) is a prevalent ocular condition associated with systemic inflammation, and the gut–eye axis has emerged as a potential therapeutic target. This randomized, double-blind, placebo-controlled trial evaluated the efficacy and safety of LB-101, a probiotic complex comprising Lactiplantibacillus plantarum NK151 and Bifidobacterium bifidum NK175, in adults with DED. Eighty participants were randomized to LB-101 or placebo once daily for 8 weeks, of whom 62 participants completed the study and were included in the final efficacy analysis. After 8 weeks, the LB-101 group demonstrated a statistically significant improvement in tear break-up time compared to placebo (mean difference: 1.01 s, 95% CI 0.01–2.01, p = 0.047). Significant improvements were also observed in certain individual symptom-level Ocular Surface Disease Index (OSDI) items. However, total OSDI scores and most other objective ocular surface endpoints did not differ significantly between the groups. Exploratory gut microbiota analysis revealed a significant increase in Carnobacteriaceae and a decrease in the endotoxin-producing bacterial family Oxalobacteraceae in the LB-101 group. No serious adverse events occurred. In conclusion, oral administration of LB-101 for 8 weeks improved tear film stability and certain symptom-level OSDI items, although total OSDI and most objective endpoints remained nonsignificant, with exploratory microbiome findings supporting the therapeutic relevance of the gut–eye axis in DED.
Source: Scientific Reports
Language: English
Subfield: Ophthalmology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,690
Award: G7544394467
OpenAlex ID: W7225988421
